Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...

Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell ...

AbbVie and Xilio Therapeutics have inked a collaboration and option-to-license agreement potentially worth more than $2 billion to clinical-stage biotechnology company Xilio.

The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...